Draft Guidance Addresses Company Requests For Rationale Of FDA Decisions

The document offers FDA’s interpretation of the terms “substantive summary” and “significant decisions,” both of which appear in new statutory provisions related to the longstanding process for manufacturers to appeal an agency decision.